statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI (maralixibat) oral solution in patients with PFIC was published in The...

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter...

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright reiterated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM - Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently...

HC Wainwright Reaffirms "Buy" Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mirum Pharmaceuticals participates in a conference call with JPMorgan

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has recommended public...

Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM Research Report) and Rocket Pharmaceuticals...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM  Get Free Report) CFO Eric Bjerkholt purchased 2,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were purchased at an...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt Purchases 2,000 Shares

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 12.5% in that time frame, underperforming the S&P 500.Will the recent negative...

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

This price move could be a signal that MIRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Mirum Pharmaceuticals (MIRM, $24.89) price may climb as it broke lower Bollinger Band on Mar 26, 2024

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Watchers	1,426
52-Wk Low	$23.14
52-Wk High	$35.56

Volume	3,707.00
52-Wk High	$35.56
52-Wk Low	$23.14

MIRM Mirum Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals